P/E ratio for Catalyst Pharmaceuticals (CPRX)
P/E ratio as of April 2024 (TTM): 13.5
According to Catalyst Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.5364. At the end of 2022 the company had a P/E ratio of 23.3.
P/E ratio history for Catalyst Pharmaceuticals from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 23.3 | 30.5% |
| 2021 | 17.8 | 284.05% |
| 2020 | 4.64 | -61.65% |
| 2019 | 12.1 | -314.21% |
| 2018 | -5.65 | -68.23% |
| 2017 | -17.8 | 289.31% |
| 2016 | -4.57 | -53.42% |
| 2015 | -9.80 | -20.81% |
| 2014 | -12.4 | 71.35% |
| 2013 | -7.22 | 113.38% |
| 2012 | -3.38 | -23.91% |
| 2011 | -4.45 | -1.15% |
| 2010 | -4.50 | 250% |
| 2009 | -1.29 | -42.14% |
| 2008 | -2.22 | -78.74% |
| 2007 | -10.5 | -22.08% |
| 2006 | -13.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -23.36% | 🇺🇸 USA |
 Pfizer PFE | 13.7 | 0.84% | 🇺🇸 USA |
 Abbott Laboratories ABT | 36.2 | 167.22% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -16.5 | -221.71% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -100.50% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 104 | 668.72% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.